PharmaShots Weekly Snapshots (May 12, 2025 – May 16, 2025)
This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A & Animal Health. Check out our full report below:
Johnson & Johnson Reveals P-III (ICONIC-TOTAL) Trial Data of Icotrokinra for Plaque Psoriasis
Read More: J&J
AstraZeneca Reports P-III (POTOMAC) Trial Findings of Imfinzi Regimen for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Read More: AstraZeneca
Novo Nordisk Reports P-III (REAL8) Basket Trial Data of Sogroya for Children with Growth Disorders
Read More: Novo Nordisk
Genentech Reports P-III (APHINITY) Trial Data of Perjeta Regimen for Early-Stage Breast Cancer
Read More: Genentech
Cytokinetics Reports P-III (MAPLE-HCM) Trial Data of Aficamten for Obstructive Hypertrophic Cardiomyopathy
Read More: Cytokinetics
Herantis Pharma Reports First Patient Dosing in P-Ib Trial of HER-096 for Parkinson’s Disease
Read More: Herantis Pharma
Merck Reports P-III (KEYNOTE-B96/ENGOT-ov65) Trial Findings on Keytruda for Platinum-Resistant Ovarian Cancer
Read More: Merck
ArkBio Reports P-II Study Data Evaluating AK3280 to Treat Idiopathic Pulmonary Fibrosis (IPF)
Read More: ArkBio
Bayer Submits MAA of Eylea 8mg to Japan’s MHLW for Treating Macular Edema Secondary to Retinal Vein Occlusion (RVO)
Read More: Bayer
UK’s MHRA Approves AstraZeneca’s Trixeo Aerosphere with Near-Zero GWP Propellant for Chronic Obstructive Pulmonary Disease (COPD)
Read More: AstraZeneca
MavriX Bio Reports the US FDA’s IND Clearance of MVX-220 for Angelman Syndrome
Read More: MavriX Bio
Sarepta Therapeutics Reports the MHLW’s Conditional & Time-Limited Approval of Elevidys for Duchenne Muscular Dystrophy (DMD)
Read More: Sarepta Therapeutics
REGENXBIO Reports the US FDA’s BLA Acceptance and Priority Review of RGX-121 for Treating Mucopolysaccharidosis II
Read More: REGENXBIO
Merck’s Welireg Receives the US FDA’s Approval for Pheochromocytoma and Paraganglioma
Read More: Merck
AbbVie’s Emrelis Receives the US FDA’s Accelerated Approval for NSCLC With High c-Met Protein Overexpression
Read More: AbbVie
The US FDA Approves Incyte’s Zynyz to Treat Adults with Squamous Cell Anal Carcinoma (SCAC)
Read More: Incyte
Travere Therapeutics Reports the US FDA’s sNDA Acceptance of Filspari for Focal Segmental Glomerulosclerosis (FSGS)
Read More: Travere Therapeutics
BioCryst Reports the US FDA’s NDA Acceptance and Priority Review of Orladeyo for Hereditary Angioedema (HAE)
Read More: BioCryst
LENZ Therapeutics Collaborates with Lotus Pharmaceutical to Commercialize LNZ100 in the Republic of Korea and Southeast Asia
Read More: LENZ Therapeutics and Lotus Pharmaceutical
Spice Biotechnologies Partners with AbTherx to Discover Antibodies in Immuno-Oncology
Read More: Spice Biotechnologies and AbTherx
GSK to Acquire Efimosfermin Alfa from Boston Pharmaceuticals for ~$2B, Strengthening its Hepatology Pipeline
Read More: GSK and Boston Pharmaceuticals
Novo Nordisk Enters a ~$2.2B Deal with Septerna to Develop Oral Small Molecules for Cardiometabolic Diseases
Read More: Novo Nordisk and Septerna
AbbVie Partners with ADARx Pharmaceuticals to Develop siRNA Therapies Across Multiple Disease Areas
Read More: AbbVie and ADARx Pharmaceuticals
Rznomics Partners with Eli Lilly for RNA Editing Therapeutics
Read More: Rznomics and Eli Lilly
Teal Health Reports the US FDA’s Approval of Teal Wand for Cervical Cancer Screening
Read More: Teal Health
Mentice Reports US Launch of Ankyras 4.0 to Advance Patient-Specific Aneurysm Planning for Neuro Interventions
Read More: Mentice
Median Technologies Seeks the US FDA’s 510(k) Clearance of eyonis LCS for Lung Cancer Detection
Read More: Median Technologies
Genesys Spine Unveils Stasys-C 3DP Cervical Standalone System to Streamline Anterior Cervical Procedures
Read More: Genesys Spine
QIAGEN to Acquire Genoox for ~$80M
Read More: QIAGEN and Genoox
TelmyVet and PetPace Launch Quality-of-Life Consultation to Support Pets and Families in End-of-Life Care
Read More: TelmyVet and PetPace
Related Post: PharmaShots Weekly Snapshots (April 28, 2025 – May 02, 2025)
